Abstract:Abstract Glioma is the most frequent tumor in central nervous system (CNS), which makes up about 30% of CNS tumors. The current standard strategy for glioma treatment is surgery plus adjuvant chemotherapy and concurrent radiotherapy. Even though, the prognosis of glioma is still poor. It’s encouraging that temozolomide (TMZ) prolongs the overall survival of glioma patients, but the following TMZ resistance is really frustrating. It’s urgent to figure out efficient ways to improve the long term prognosis of patients, such as antagonizing the TMZ resistance. Ferroptosis was a newly discovered type of regulated cell death characterized by iron-dependent aberrant lipid peroxidation and membrane damage in the last decade. Ferroptosis-associated iron transport proteins modulate the process precisely through controlling the iron content. ZIP14, also known as SLC39A14, is an eight-transmembrane protein which could transport divalent metal ion like Mn2+, Zn2+ and Fe2+. Our preliminary data showed that the expression level of ZIP14 was higher in tumor tissues than paired normal tissue, which was corelated with poor prognosis of glioma. Knock down ZIP14 could induce cell death, and which could be rescued by inhibitors for ferroptosis but not for apoptosis or necrosis. Knock down ZIP14 decreased the ferroptosis inhibition by Ferroptosis suppress protein 1 (FSP1) which through reduction of lipid peroxidation, and sensitized cells to TMZ. Furthermore, we found that ZIP14 formed a complex with Ubiquinone. And it was known that FSP1 is critical in the switch of ubiquinone to ubiquinol. Therefore, we propose that ZIP14 suppress lipid peroxidation through blockage of the transition of ubiquinone to ubiquinol. While ZIP14 was knocked down, the complex with Ubiquinone wad damaged, and could not further change to Ubiquinol, so the suppression to lipid peroxidation was released, and then, ferroptosis was upregulated. In this study, we are going to figure out the molecular mechanism about how ZIP14 suppress ferroptosis and find out efficient small molecule inhibitors to activate ferroptosis by abolishing ZIP14 and improve the prognosis of glioma patients. Citation Format: Jing Wang. Targeting the suppressor of ferroptosis to improve the treament effeciency of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 361.

Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme

Preparation of transferrin-targeted temozolomide nano-micelles and their anti-glioma effect

Fe-MOF Nanoplatform: Specifically Overcoming Oxaliplatin Resistance in Colorectal Cancer Through Multifaceted Pathways

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance

Tumor targeted cancer membrane-camouflaged ultra-small Fe nanoparticles for enhanced collaborative apoptosis and ferroptosis in glioma

Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma

LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis

Theranostic Nanomedicine for Synergistic Chemodynamic Therapy and Chemotherapy of Orthotopic Glioma

Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells

Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis

Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia

Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme

A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma

Enhanced glioma cell death with ZnO nanorod flowers and temozolomide combination therapy through autophagy and mitophagy pathways

ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

Abstract 361: Targeting the suppressor of ferroptosis to improve the treament effeciency of glioblastoma